Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
exendin-4 + human [Leu15]gastrin-17
- Development stage
- Preclinical
- Lead developer
- Zealand Pharma
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
exendin-4 + human [Leu15]gastrin-17 is a preclinical combination therapy consisting of exendin-4, a glucagon-like peptide-1 receptor (GLP-1R) agonist, and human [Leu15]gastrin-17, a cholecystokinin B receptor (CCK2R) agonist. Developed by Zealand Pharma, this combination leverages the synergistic effects of GLP-1R and CCK2R dual activation to promote pancreatic beta-cell proliferation, enhance islet cell survival, and improve glycemic control. Preclinical studies in rodent models of diabetes have demonstrated that co-administration of these two peptides significantly increases beta-cell mass and protects against palmitate- and cytokine-induced apoptosis, suggesting therapeutic potential for the treatment and prevention of Type 2 diabetes.
- Other names
- exendin-4 + [Leu15]gastrin-17exendin-4 + [Leu15]gastrin17exendin-4 + h[Leu15]gastrin-17exendin-4 + h[Leu15]gastrin17exendin-4 and h[Leu15]gastrin-17exendin-4 and h[Leu15]gastrin17exendin-4 and human [Leu15]gastrin-17exendin-4/h[Leu15]gastrin-17exendin-4/h[Leu15]gastrin17exendin-4/human [Leu15]gastrin-17
02
Targets
CCK2R (Cholecystokinin 2 Receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on exendin-4 + human [Leu15]gastrin-17.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on exendin-4 + human [Leu15]gastrin-17.